证券代码： 600566 证券简称： 济川药业 公告编号： 2025-042 湖北济川药业股份有限公司 关于收到要约收购报告书的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 2025 年 6 月 11 日，公司实际控制人曹龙祥先生与其子曹飞先生签署《江 苏济川控股集团有限公司股权转让协议》，曹龙祥先生拟将其所持江苏 济川控股集团有限公司（以下简称"济川控股"）10.10%的股权转让给 曹飞先生。本次股权转让完成后，曹飞先生持有济川控股 60%的股权， 成为济川控股的控股股东，并通过济川控股、西藏济川企业管理有限公 司（以下简称"西藏济川"）间接控制上市公司 516,757,360 股股份， 占上市公司总股本的 56.07%，超过上市公司已发行股份的 30%，从而 触发全面要约收购义务。 本次股权转让系公司实际控制人曹龙祥先生向其子曹飞先生转让部分 济川控股股权，属于实际控制人家族内部的股权结构调整行为，不会影 响公司的独立性，不会对公司经营产生重大影响。本次转让完成后，上 市公司控股股东不变， ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-043 湖北济川药业股份有限公司 关于曹飞先生要约收购公司股份的申报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 湖北济川药业股份有限公司（以下简称"济川药业"或"公司"）于 2025 年 6 月 12 日收到曹飞先生(以下简称"收购人")发来的《湖北济川药业股份有 限公司要约收购报告书》(以下简称"《要约收购报告书》")等文件，就收购人 要约收购的有关事项作出申报公告如下: 一、 本次要约收购申报的有关事项 （一）要约收购的提示 《要约收购报告书》披露后 30 日内，本公司将在上海证券交易所网站 （http://www.sse.com.cn）发布 3 次要约收购提示性公告。 （二）要约收购情况 1 预受要约申报代码：706034 申报简称：济川收购 要约收购支付方式：现金 要约收购价格：26.93 元/股 要约收购数量：全面要约，拟收购股份数量为 350,841,357 股，占济川 药业总股份的比例为 38.06%。 要约收购有效期 ...

证券简称：济川药业 证券代码：600566.SH 湖北济川药业股份有限公司 要约收购报告书 | 上市公司名称： | 湖北济川药业股份有限公司 | | --- | --- | | 股票上市地点： | 上海证券交易所 | | 股票简称： | 济川药业 | | 股票代码： | 600566.SH | | 收购人： 曹飞 | | | --- | --- | | 住所 ： | 上海市黄浦区**** | | 一致行动人： 曹龙祥 | | | 住所 ： | 江苏省泰兴市**** | | 一致行动人： | 江苏济川控股集团有限公司 | | 住所 ： | 泰兴市黄桥工业园区兴业标房 号厂房内 1 | | 一致行动人： | 西藏济川企业管理有限公司 | | 住所 ： | 拉萨经济技术开发区大连路以西、格桑路以北总部 | | | 经济基地 B（栋）3 单元 4 层 404 号 | 收购方财务顾问： 签署日期：二零二五年六月 湖北济川药业股份有限公司 要约收购报告书 特别提示 本部分所述的词语或简称与本报告书"释义"部分所定义的词语或简称具 有相同的含义。 1、本次股权转让前，济川控股持有上市公司 416,757,360 股股份（占 ...

北京植德律师事务所 关于 《湖北济川药业股份有限公司要约收购报告书》的 法律意见书 植德(证)字[2025]0024-1 号 | 释 人 | | --- | | 一、收购人及其一致行动人的基本情况 | | 二、要约收购的目的 . | | 三、要约收购方案 . | | 四、收购资金来源 . | | 五、后续计划 . | | 六、对上市公司的影响分析 . | | 七、与上市公司之间的重大交易 . | | 八、前六个月内买卖上市公司股份的情况 . | | 九、《要约收购报告书》的格式与内容 | | 十、参与本次要约收购的专业机构 | | 十一、结论意见 | l 释 义 本法律意见书中,除非文义另有所指,下列词语或简称具有如下含义: | 济川药业、公司、上市公司 | 분 | 湖北济川药业股份有限公司 | | --- | --- | --- | | 收购人 | 블 | ■ K | | 济川控股 | 指 | 江苏济川控股集团有限公司 | | 西藏济川 | 指 | 西藏济川企业管理有限公司 | | 一致行动人 | 指 | 曹龙祥、济川控股、西藏济川 | | 本次股权转让/本次转让 | 指 | 曹龙祥将其持有的济川控股10. ...

曹飞 要约收购 北京博星证券投资顾问有限公司 关于 湖北济川药业股份有限公司 之 财务顾问报告 二〇二五年六月 北京博星证券投资顾问有限公司 财务顾问报告 重要提示 本部分所述的词语或简称与本报告书"释义"部分所定义的词语或简称具有相 同的含义。 1、本次股权转让前，济川控股持有上市公司 416,757,360 股股份（占上市公司 总股本的 45.22%），为上市公司控股股东，曹龙祥持有济川控股 50.10%股权为其 控股股东，曹飞持有济川控股 49.90%股权；西藏济川为济川控股全资子公司，持有 上市公司 100,000,000 股股份（占上市公司总股本的 10.85%）；曹龙祥持有上市公 司 46,838,458 股股份（占上市公司总股本的 5.08%）。本次股权转让前，上市公司 实际控制人为曹龙祥，曹龙祥与收购人曹飞系父子关系。 2025 年 6 月 11 日，曹龙祥与曹飞签署《股权转让协议》，曹龙祥将其持有的 济川控股 10.10%股权以 1,010 万元价格转让给曹飞，股权转让完成后，曹飞持有济 川控股 60%股权，为济川控股控股股东，并通过济川控股、西藏济川间接控制上市 公司 516,757,36 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The flu virus is a highly pathogenic pathogen, and the development of new mechanism drugs is imperative [4] - The flu is a common respiratory infectious disease with a high transmission rate, affecting approximately 1 billion people globally each year, with 300,000 to 500,000 severe cases and 290,000 to 650,000 deaths due to flu-related respiratory diseases [4][15] - The domestic flu drug market has exceeded 10 billion yuan, with Oseltamivir holding over 80% market share, while Baloxavir has seen rapid growth from 0.07 billion yuan in 2022 to 0.63 billion yuan in 2023 [6][36] Summary by Sections 1. Flu Virus and Drug Development - The flu virus is categorized into four types: A, B, C, and D, with A and B being the primary types responsible for widespread outbreaks [17][20] - The main drug targets during flu infection include the surface proteins Hemagglutinin (HA) and Neuraminidase (NA), with RNA polymerase inhibitors emerging as the mainstream research target in antiviral drug development [5][26] 2. Market Dynamics - The flu drug market in China is projected to grow significantly, with new domestic drugs expected to launch in 2025, enhancing sales potential and company performance [7][36] - The sales of flu drugs in the domestic market reached 11.405 billion yuan in 2023, with Oseltamivir accounting for 86.48% of the market share [36] 3. Investment Recommendations - Recommended stocks include Jichuan Pharmaceutical and Health元, with beneficiaries including Zhongsheng Pharmaceutical and Xiansheng Pharmaceutical [7]

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Core Viewpoint - The announcement details a change in the shareholding structure of Hubei Jichuan Pharmaceutical Co., Ltd., where the actual controller changes from Mr. Cao Longxiang to Mr. Cao Fei and Mr. Cao Longxiang due to a family internal asset arrangement [1][3]. Group 1: Shareholding Structure Changes - Mr. Cao Longxiang plans to transfer 10.10% of his shares in Jichuan Holdings to his son, Mr. Cao Fei, resulting in Mr. Cao Longxiang holding 40% and Mr. Cao Fei holding 60% of Jichuan Holdings [1][3]. - As of the announcement date, Jichuan Holdings holds 416,757,360 shares of the company, accounting for 45.22% of the total share capital [1]. - The combined shareholding of Jichuan Holdings and its concerted actors, including Tibet Jichuan Enterprise Management Co., Ltd. and Mr. Cao Longxiang, totals 563,595,818 shares, representing 61.15% of the total share capital [1]. Group 2: Impact of Changes - The change in shareholding structure does not alter the controlling shareholder, which remains Jichuan Holdings, and the actual controllers are now Mr. Cao Fei and Mr. Cao Longxiang [2][3]. - The internal asset arrangement will not affect the company's operational stability, independence, or ongoing viability [2][3]. - Following the share transfer, Mr. Cao Fei will hold 56.07% of the company's shares through Jichuan Holdings and Tibet Jichuan, triggering his obligation for a mandatory tender offer [3][4].

Core Viewpoint - The company has received a tender offer report summary from Mr. Cao Fei, which triggers a mandatory tender offer due to changes in shareholding structure [2][3][5]. Group 1: Tender Offer Details - The tender offer price is set at 26.93 yuan per share, with a total of 350,841,357 shares being offered, representing 38.06% of the company's issued shares [5][6]. - The tender offer period is 30 calendar days, during which investors can check the number of shares accepted for the offer [8]. - The offer is aimed at acquiring all freely tradable shares held by shareholders other than Mr. Cao Longxiang, Jichuan Holdings, and Tibet Jichuan [5][6]. Group 2: Shareholding Changes - Mr. Cao Longxiang plans to transfer 10.10% of his shares in Jichuan Holdings to his son, Mr. Cao Fei, making Mr. Cao Fei the controlling shareholder of Jichuan Holdings with 60% ownership [3][4]. - Following the transfer, Mr. Cao Fei and Mr. Cao Longxiang will jointly control 56.07% of the listed company, triggering the mandatory tender offer obligation [3][5]. Group 3: Financial Arrangements - The total maximum funding required for the tender offer is based on the offer price and is sourced from the acquirer's own funds and legally raised funds [7]. - Mr. Cao Fei has deposited 1.895 billion yuan as a performance guarantee for the tender offer, which is at least 20% of the total required funds [7].

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-038 湖北济川药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北济川药业股份有限公司（以下简称"公司"）于近日收到华泰联合证券 有限责任公司（以下简称"华泰联合证券"）出具的《华泰联合证券有限责任公 司关于更换湖北济川药业股份有限公司 2020 年向特定对象发行股票持续督导保 荐代表人的函》,华泰联合证券作为公司 2020 年向特定对象发行股票的保荐机构， 原指定龙伟先生、周小金先生担任该项目的保荐代表人负责持续督导工作,持续督 导期至 2021 年 12 月 31 日止。鉴于本次发行的募集资金尚未使用完毕，华泰联合 证券仍对募集资金使用情况继续履行持续督导义务。 现因龙伟先生工作调动，不能继续担任持续督导期的保荐工作。为保证持续 督导工作的有序进行，华泰联合证券委派保荐代表人俎春雷先生（简历附后）接 替龙伟先生履行持续督导职责。 特此公告。 湖北济川药业股份有限公司董事会 附件:俎春雷个人简历 本次变 ...